GlaxoSmithKline, Vir Biotechnology poised to fight Omicron and raise their stock prices

Posted: 17 December 2021 5:30 am
News
HumanHandsInProtectivePurpleGlovesInjecting_GettyImages_1800x1000

Two companies offering COVID variant treatment may give them an edge and boost their stocks over other drug companies.

The World Health Organization (WHO) recently reported that the covid vaccines may be less effective against the Omicron variant. What's more, monoclonal antibodies from multiple biotech companies, including Regeneron, had almost completely lost their neutralizing ability, according to one research paper.

According to the paper, sotrovimab, a monoclonal antibody developed by GlaxoSmithKline (ADR: GSK) and Vir Biotechnology (VIR), is still effective against the Omicron variant.

What this means for the stocks

If the Omicron variant does avoid vaccine-induced immunity like the preliminary data suggests, we may see a rising need for boosters and other pharmaceuticals to prevent hospitalizations.

Aside from vaccines, sotrovimab may be the go-to treatment if the data within the research paper is correct. If real-world data confirm these findings in the future, these two companies could see their stock prices skyrocket.

One caution sign: The research paper isn't yet peer-reviewed, and some researchers involved were either employed by or owned shares of Vir Biotechnology. This could mean biased research.

COVID vaccine stocks still outperform the market

Since the market crash in 2020, GSK stock has gained 30%, but it hasn't yet reached pre-crash levels. But Vir didn't take a huge hit in the crash. Regardless, the stock is up 50% since late March 2020.

Both are still way behind BioNTech (ADR: BNTX), which is up 421% within the same period, and Pfizer (PFE), which is up 113%. What's more, Pfizer announced a new pill effective against the Omicron variant, which could lead to even more gains for that company.

What do analysts think about GSK and Vir?

Analysts haven't yet upgraded GlaxoSmithKline stock on this news. The analyst consensus is to hold the stock with a target of US$46 per share — a mere 6% higher than the current market price. On the other hand, Vir has a buy rating and an average analyst target of US$77 per share, which is 41% more than the current price.

Need a better share trading platform? Check out Finder's full review of the best online brokers in Australia right now.

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

Get more from Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site